"Bad luck" delayed Leo Pharma's prize candidate for eight months

When the FDA tightened up requirements for medical devices midway through evaluating Leo Pharma's tralokinumab, the dermatology company scrambled to collect data on the pre-filled injection pen used to administer the eczema treatment.

Photo: Leo Pharma / PR

Sudden and unexpected requirements from the FDA for more data on the protective cap for the syringe used to inject Leo Pharma's eczema treatment meant the product was first launched in the US at Christmas -- more than eight months later than expected.

Jörg Möller, head of research and development, does not think that Leo Pharma could have done anything to change this.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs